Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
COA published
- Arrives Thu, Oct 22 – Tue, Oct 27Free standard shipping on orders over $100
- Free shipment protectionLost, stolen, or damaged? We replace it, on us.
- Overnight and 2-day optionsPick your speed at checkout
Tesamorelin
Secretagogue Peptide
A stabilized analog of full-length growth hormone-releasing hormone (GHRH 1-44) carrying a trans-3-hexenoyl group at the N-terminus. It is used in research on GHRH-receptor signaling, growth hormone release and visceral fat metabolism. For in vitro laboratory research use only.
- Arrives Thu, Oct 22 – Tue, Oct 27Free standard shipping on orders over $100
- Free shipment protectionLost, stolen, or damaged? We replace it, on us.
- Overnight and 2-day optionsPick your speed at checkout
Certificate of Analysis
Third Party Tested ISO/IEC 17025 ACCREDITED
Compound Information
What is Tesamorelin?
- CAS number
- 218949-48-5
- Molecular weight
- 5,135.9 g/mol
- Amino acids
- 44
- Formula
- C221H366N72O67S
- Sequence
- 44-residue human GHRH(1-44) amide, N-terminally acylated with a trans-3-hexenoyl group
Stability information
- Protect from light
- Avoid repeated freeze-thaw cycles
Conditions apply to sealed research vials as supplied. Batch details are on the Certificate of Analysis above.
Sources & References
Peer-reviewed research
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy
View Source ↗Tesamorelin, a human growth hormone releasing factor analogue
View Source ↗Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor
View Source ↗The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV
View Source ↗Advances in the detection of growth hormone releasing hormone synthetic analogs
View Source ↗Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
View Source ↗Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
View Source ↗Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
View Source ↗Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers
View Source ↗Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
View Source ↗Frequently Researched Together
Related research compounds
GLP-2 (TR)
Metabolic Research Peptide
Kisspeptin
Secretagogue Peptide
MOTS-C
Mitochondrial-derived peptide
Ipamorelin
Selective GH secretagogue
Cagrilintide
Long-acting amylin analog
GLP-3 (RT)
Triple-agonist metabolic research peptide
Recon Water
Research Supplies
IGF-1 LR3
Long-acting IGF-1 analog
CJC-1295 / Ipamorelin (No DAC)
Secretagogue Peptide